Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol.

Knorr M, Hausding M, Schulz E, Oelze M, Rümmler R, Schuff A, Daub S, Schreiner J, Kröller-Schön S, Wenzel P, Gori T, Burgin K, Sartor D, Scherhag A, Münzel T, Daiber A.

Pharmacology. 2012;90(3-4):193-204. doi: 10.1159/000339861. Epub 2012 Sep 13.

PMID:
23038657
2.

In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone.

Knorr M, Hausding M, Pfeffer A, Jurk K, Jansen T, Schwierczek K, Oelze M, Kröller-Schön S, Schulz E, Wenzel P, Gori T, Burgin K, Sartor D, Scherhag A, Münzel T, Daiber A.

Pharmacology. 2014;93(5-6):203-15. doi: 10.1159/000361052. Epub 2014 Jun 7.

PMID:
24923291
3.

Basic in vitro Characterization of the Vasodilatory Potential of 2-Aminoethyl Nitrate Fixed-Dose Combinations with Cilostazol, Metoprolol and Valsartan.

Oelze M, Welschof P, Knorr M, Tran LP, Ullmann E, Stamm P, Kröller-Schön S, Jansen T, Kopp M, Schulz E, Gori T, Burgin K, Scherhag A, Sartor D, Münzel T, Daiber A.

Pharmacology. 2018;101(1-2):54-63. doi: 10.1159/000480434. Epub 2017 Oct 7.

PMID:
28988245
4.

Organic nitrates and nitrate tolerance--state of the art and future developments.

Daiber A, Münzel T, Gori T.

Adv Pharmacol. 2010;60:177-227. doi: 10.1016/B978-0-12-385061-4.00007-6. Review.

PMID:
21081219
5.

New organic nitrate-containing benzyloxy isonipecotanilide derivatives with vasodilatory and anti-platelet activity.

de Candia M, Marini E, Zaetta G, Cellamare S, Di Stilo A, Altomare CD.

Eur J Pharm Sci. 2015 May 25;72:69-80. doi: 10.1016/j.ejps.2015.03.004. Epub 2015 Mar 10.

6.

Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits.

Serebruany VL, Malinin AI, Lowry DR, Sane DC, Webb RL, Gottlieb SO, O'Connor CM, Hennekens CH.

J Cardiovasc Pharmacol. 2004 May;43(5):677-84.

PMID:
15071355
7.

Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates.

Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov AL, Stalleicken D, Ullrich V, Mülsch A, Münzel T.

Mol Pharmacol. 2004 Dec;66(6):1372-82. Epub 2004 Aug 26.

8.

Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Daiber A, Münzel T.

Antioxid Redox Signal. 2015 Oct 10;23(11):899-942. doi: 10.1089/ars.2015.6376. Epub 2015 Sep 24. Review.

9.

Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.

Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL.

J Hypertens. 2008 Feb;26(2):322-33. doi: 10.1097/HJH.0b013e3282f16aaf.

PMID:
18192847
10.

Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.

Koenig A, Lange K, Konter J, Daiber A, Stalleicken D, Glusa E, Lehmann J.

J Cardiovasc Pharmacol. 2007 Jul;50(1):68-74.

PMID:
17666918
11.

Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance.

Csont T, Ferdinandy P.

Pharmacol Ther. 2005 Jan;105(1):57-68. Review.

PMID:
15626455
12.

Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.

Gerzer R, Drummer C, Karrenbrock B, Heim JM.

J Cardiovasc Pharmacol. 1989;14 Suppl 11:S115-9.

PMID:
2484688
13.

Structure-activity relationship of organic nitrates for activation of guanylate cyclase.

Schröder H, Noack E.

Arch Int Pharmacodyn Ther. 1987 Dec;290(2):235-46.

PMID:
2895614
14.

More answers to the still unresolved question of nitrate tolerance.

Münzel T, Daiber A, Gori T.

Eur Heart J. 2013 Sep;34(34):2666-73. doi: 10.1093/eurheartj/eht249. Epub 2013 Jul 17. Review.

PMID:
23864131
15.

Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction.

Münzel T, Steven S, Daiber A.

Vascul Pharmacol. 2014 Dec;63(3):105-13. doi: 10.1016/j.vph.2014.09.002. Epub 2014 Oct 14. Review.

PMID:
25446162
17.

A new class of organic nitrates: investigations on bioactivation, tolerance and cross-tolerance phenomena.

Schuhmacher S, Schulz E, Oelze M, König A, Roegler C, Lange K, Sydow L, Kawamoto T, Wenzel P, Münzel T, Lehmann J, Daiber A.

Br J Pharmacol. 2009 Sep;158(2):510-20. doi: 10.1111/j.1476-5381.2009.00303.x. Epub 2009 Jun 25. Erratum in: Br J Pharmacol. 2013 Jun;169(4):952.

18.

New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance.

Daiber A, Wenzel P, Oelze M, Münzel T.

Clin Res Cardiol. 2008 Jan;97(1):12-20. Epub 2007 Oct 19. Review.

PMID:
17938848
19.

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.

Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J.

Br J Pharmacol. 1993 Oct;110(2):761-71.

20.

Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo.

Mülsch A, Bara A, Mordvintcev P, Vanin A, Busse R.

Br J Pharmacol. 1995 Nov;116(6):2743-9.

Supplemental Content

Support Center